SM
Therapeutic Areas
Nutriband Pipeline
| Drug | Indication | Phase |
|---|---|---|
| AVERSA Fentanyl Patch | Chronic Pain (with abuse-deterrent properties) | Phase 1/2 |
| AVERSA Technology Platform | Abuse-deterrent formulation for other transdermal opioids & drugs with abuse potential | Preclinical |
| Transdermal Biologics/Injectable Conversion | Various chronic diseases requiring injectable biologics | Preclinical |
Leadership Team at Nutriband
GS
Gareth Sheridan
Founder and CEO
DA
Dr. Alan Smith
COO, President of 4P Therapeutics
DJ
Dr. Jeff Patrick
Chief Scientific Officer (CSO)
GG
Gerald Goodman
Chief Financial Officer (CFO)
MM
Michael Myer
President, Pocono Pharmaceutical
TO
Tyler Overk
Head of Active Intelligence
MH
Mark Hamilton
Member, Board of Directors
DS
Dr. Stefani Mancas
Member, Board of Directors
IG
Irina Gram
Member, Board of Directors
AP
Allesandro Puddu
Member, Board of Directors